近十年中成药药物经济学研究文献分析及质量评价

Pharmacoeconomics Research Literature Analysis and Quality Evaluation of Chinese Patent Medicine in Recent Ten Years

目的通过分析与评价2012年以来发表的中成药药物经济学研究文献的核心要素及文献质量,探究目前中成药药物经济学研究存在的问题。方法从中国期刊全文数据库、万方数据知识服务平台、中文期刊全文数据库、中国生物医学文献服务系统、PubMed、Web of Science、Cochrane Library中检索2012年1月至2022年11月发表的中成药药物经济学研究相关文献,对研究角度、研究时限、贴现、阈值、成本、健康产出指标、评价方法、模型和敏感性分析等经济性评价关键要素进行系统整理、归纳和分析,并采用《卫生经济学评价报告标准共识2022清单》(CHEERS 2022)进行文献质量评价。结果纳入的288篇文献中,评价剂型以中药注射剂最多,同时包含同一中成药不同剂型之间的对比;病种主要集中于心脑血管和呼吸系统疾病;评估要素分析显示中成药药物经济学研究存在研究角度不明确、成本测算简略、健康产出指标单一等问题;CHEERS评价显示,文献质量整体较低,平均分为14.33分(总分28分),仅87篇合格。结论我国中成药药物经济学研究文献总体报告质量较差,未来仍需加强药物经济学评价核心要素的研究,不断提高研究和报告质量,整合中医药特色评估要素,以促进中成药药物经济学研究的高质量发展。

Objective By analyzing the evaluation factors of published Chinese patent medicine pharmacoeconomics literature and evaluating the literature quality,the existing problems in pharmacoeconomics research of Chinese patent medicine were explored.Methods Literature related to pharmacoeconomics of Chinese patent drugs published in CNKI、Wanfang、VIP、PubMed、Web of Science、Cochrane Library was searched,and the retrieval time was set from January 2012 to November 2022.The Consolidated Health Economic Evaluation Reporting Standards 2022(CHEERS 2022)was used to evaluate the quality by systematically organizing,concluding and analyzing key factors in economic evaluation,including research perspectives,research duration,discounting,thresholds,costs,health output indicators,evaluation methods,models and sensitivity analysis.Results Among the 288 literatures included,TCM injection was the most evaluated dosage form,and the comparison between different dosage forms of the same proprietary Chinese medicine was also included.The main diseases were cardiovascular and cerebrovascular diseases and respiratory diseases.The evaluation factor analysis showed that there were some problems in the pharmacoeconomics of PCM,such as unclear research Angle,simple cost calculation and single health output index.CHEERS evaluation showed that the literature quality was generally low,with an average score of 14.33(out of 28),and only 87 articles were qualified.Conclusion The overall report quality of Chinese patent medicine pharmacoeconomics research literature is poor.In the future,it is still necessary to strengthen the research on the core elements of pharmacoeconomics evaluation,constantly improve the quality of research and report,and integrate the evaluation elements of TCM characteristics,so as to promote the high-quality development of pharmacoeconomics research of Chinese patent medicine.